National Center Reports Increase in Medical Device Adverse Event Reports for 2022
The National Center for Adverse Event Monitoring has released its national annual report regarding the...
China’s NMPA, MPS, and NHC Announce Updates to Narcotics and Psychotropic Substances Catalog
The National Medical Products Administration (NMPA), Ministry of Public Security, and National Health Commission have...
China Resources Biopharmaceutical Partners with Hefei Institute and Afana Bio for Joint Lab
China Resources Biopharmaceutical Co., Ltd has announced a strategic partnership with the Hefei Comprehensive National...
XZenith Biopharm Completes Enrollment in Phase II Study for Proton Pump Inhibitor
XZenith Biopharm, a Chinese company with minority ownership by Sihuan Pharma, has completed patient enrollment...
Adagene Inc. Presents Positive Interim Results for ADG126 at AACR Annual Meeting
China-based Adagene Inc. (NASDAQ: ADAG) has announced interim results from its combination dose escalation studies...
BeiGene and SpringWorks Therapeutics Report Positive Phase Ib Results for Lifirafenib and Mirdametinib Combination
China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) and SpringWorks Therapeutics Inc., (NASDAQ: SWTX) have...
HanchorBio Receives FDA Approval for Multi-Region Clinical Study of HCB101 Fusion Protein
Taiwan-based HanchorBio has announced receiving the green light from the US FDA to conduct a...
Hainan’s Boao Lecheng Partners with Sonova to Advance Hearing Health Solutions in China
The Boao Lecheng Medical Tourism Pilot Zone of Hainan Province has struck a strategic partnership...
Nanjing Chamlion Laser Technology Secures RMB 236 Million in Series B Financing for Dental 3D Printing
Nanjing Chamlion Laser Technology Co., Ltd, a leading provider of dental metal 3D printing solutions...
HutchMed’s Elunate Receives NMPA Review for Second-Line Gastric Cancer Treatment
China-based HutchMed (HKG: 0013, NASDAQ: HCM) has announced that the National Medical Products Administration (NMPA)...
HuidaGene Receives CDE IND Approval for Ophthalmology Gene Therapy HG004
China-based HuidaGene (Shanghai) Biotechnology Co., Ltd has announced receiving Investigational New Drug (IND) approval from...
CBMG’s C-CAR031 Shows Promising Results in Phase I Study for Hepatocellular Carcinoma
China-based cell therapy specialist Cellular Biomedicine Group Inc. (CBMG) has published the results of the...
CanSino Biologics Reports 2022 Revenue Drop and Increased Losses Amid COVID-19 Vaccine Market Shifts
China-based vaccines specialist CanSino Biologics Inc., (HKG: 6185) has released its 2022 financial report, recording...
PackGene Secures Series C Financing to Boost AAV Innovation and Global Expansion
China-based PackGene Biotech has announced the successful completion of a Series C financing round, securing...
Bioworkshops Secures RMB 100 Million in Series A Financing for Biologic Drug Development
Bioworkshops, a Contract Development and Manufacturing Organization (CDMO) based in Suzhou and specializing in biologic...
Sinovation Medical’s SinoLITT System and Fiber Kit Gain NMPA Approval for Epilepsy Treatment
Sinovation (Beijing) Medical Technology Co., Ltd has announced that its in-house developed magnetic resonance monitoring...
Merck and XtalPi Leverage Molecular Dynamics to Enhance Small-Molecule Crystallization
German pharmaceutical giant Merck (NYSE: MRK) and China-based drug discovery solutions specialist XtalPi have published...
Neurophth Biotechnology Receives NMPA Approval for Phase I/II Gene Therapy Study
Neurophth Biotechnology Ltd, a leading gene therapy specialist based in China, has announced that it...
Shenzhen Core Medical Technology Secures RMB 200 Million in Series C+ Financing for Artificial Heart Tech
Shenzhen Core Medical Technology Co., Ltd, a leading Chinese manufacturer of artificial hearts, has reportedly...
Hainan Poly Pharm Wins Health Canada Approval for Generic Cytovene-IV (Ganciclovir)
Hainan Poly Pharm Co., Ltd (SHE: 300630), a China-based pharmaceutical company, has announced that it...